In 2023, there were 18 oncology and 7 population health Institute for Value-Based Medicine® events cohosted with organizations such as Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.
The American Journal of Managed Care®’s Institute for Value-Based Medicine® (IVBM) first launched in 2018, and in 2023 there were 25 events held. The meeting started as oncology-focused events, ad this year there were 7 population health events covering health inequities, primary care delivery, diabetes management, maternal care, and more.
These regional events partner with a local organization to bring together expert faculty to discuss their experiences and insights with implementing value-based care. Organizations who cohosted IVBM events this year included Optum, OneOncology, Vanderbilt Ingram Cancer Center, Duke Health, Cleveland Clinic, and Memorial Sloan Kettering Cancer Center.
Learn more about upcoming events in 2024, and see all our coverage from IVBMs.
Here is the most popular content from IVBMs in 2023.
5. How Antibody Drug Conjugates—and Chemotherapy Shortages—Are Affecting Patients With Bladder Cancer
At the July 25, 2023, IVBM with Emory Winship Cancer Institute, Jacqueline T. Brown, MD, assistant professor at the Winship Cancer Institute, explained how genitourinary malignances have become the poster child for extremes of care delivery. She covered the rise of antibody-drug conjugates and how this drug class has elevated standard of care for the sixth most common cancer, urothelial carcinoma. However, she also noted that shortages of 2 cornerstone chemotherapies, cisplatin and carboplatin, have created tough treatment decisions and brought to light health equity issues.
4. A Q&A With Dr Lucio Gordan: How Florida Cancer Specialists & Research Institute Evolved During Difficult Times
During an IVBM cohosted with Florida Cancer Specialists & Research Institute (FCS) on August 10, 2023, Lucio Gordan, MD, president and managing physician at FCS, discussed how his organization has been adapting during difficult times with a focus on the ongoing cancer drug shortages, the COVID-19 pandemic, and the aftermath of Hurricane Ian in 2022.
3. Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
Also from the August 10 IVBM event, Nathan Walcker, CEO of FCS, participated in a podcast episode of Managed Care Cast. During the interview, Walcker discussed key strategic practices and initiatives in providing high-quality community-based oncology care, including some of the recent partnerships that were set up to further this goal.
Listen to the podcast episode.
2. Championing Value-Based Primary Care: How Practices Can Support and Optimize Health Outcomes
The March 9, 2023, IVBM event held in partnership with Optum covered ways to eliminate wasteful care and build the infrastructure required to advance value-based care delivery. Ken Cohen, MD, executive director of translational research for OptumCare, and Lee A. Norman, MD, MHS, MBA, senior medical director of Optum Kansas City, served as cochairs of the event. Cohen also served as the keynote speaker and discussed the Optum Care Model, which leverages several strategies to support value-based care delivery in primary care practices.
1. Dr Stephen Schleicher: We’re at a Turning Point in Oncology Care
During an IVBM event held with New York Cancer & Blood Specialists on February 8, Stephen Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discussed the state of value-based oncology care during a time period between the end of the Oncology Care Model in 2022 and the start of the Enhancing Oncology Model (EOM), which kicked off July 1, 2023. At the time, Schleicher's practice had not committed to participating in EOM until they had analyzed practice-specific baseline data. Ultimately, Tennessee Oncology did sign up for the model as 1 of only 44 practices.
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Practical Considerations for AI in Community Oncology
July 8th 2025Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."
Read More